A pivotal trial of ANAVEX®2-73 (blarcamesine) in Parkinson's disease dementia
Latest Information Update: 16 May 2022
At a glance
- Drugs Blarcamesine (Primary)
- Indications Dementia; Parkinson's disease
- Focus Registrational; Therapeutic Use
- Sponsors Anavex Life Sciences
- 10 May 2022 According to an Anavex Life Sciences media release, the company expect to meet with FDA for discussing this study in 2022.
- 20 Oct 2020 New trial record
- 15 Oct 2020 According to an Anavex Life Sciences media release, the company is planning a pivotal trial of ANAVEX2-73 (blarcamesine) in Parkinson's disease dementia after submitting the results of the ANAVEX2-73-PDD-001 study to the FDA to obtain regulatory guidance.